Healthcare provider profile · identity verified

Jose D Quiles, MD

Allopathic & Osteopathic Physicians|General Practice · SANTA ISABEL, PR · NPI 1982673794

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Jose D Quiles, MD received $117.54 in general payments during 2025 across 4 reported records.

GlaxoSmithKline, LLC. accounted for 43.6% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$117.54

4 reported records · 3 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
GlaxoSmithKline, LLC.	Unresolved — no canonical attribution shown	$51.30	43.6%	1	2025
Otsuka America Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$51.02	43.4%	2	2025
Abbott Laboratories	Unresolved — no canonical attribution shown	$15.22	12.9%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$117.54	4

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
REXULTI Normalized: rexulti	Drug	Otsuka America Pharmaceutical, Inc.	$51.02	2	2025
Source payment records 2025-09-16 · Otsuka America Pharmaceutical, Inc. · $22.79 · Open Payments source 2025-10-20 · Otsuka America Pharmaceutical, Inc. · $28.23 · Open Payments source
ESPRIT Normalized: esprit	Device	Abbott Laboratories	$15.22	1	2025
Source payment records 2025-11-11 · Abbott Laboratories · $15.22 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference	2025	TRELEGY ELLIPTA open payments reported associated product	CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369	Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row	11	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Simvastatin	Simvastatin	1196	172
Atorvastatin Calcium	Atorvastatin Calcium	1003	155
Gabapentin	Gabapentin	961	150
Omeprazole	Omeprazole	909	128
Amlodipine Besylate	Amlodipine Besylate	790	98
Losartan Potassium	Losartan Potassium	731	107
Famotidine	Famotidine	607	93
Synthroid	Levothyroxine Sodium	590	80
Metformin Hcl	Metformin Hcl	543	79
Pantoprazole Sodium	Pantoprazole Sodium	490	71
Lisinopril	Lisinopril	420	66
Alendronate Sodium	Alendronate Sodium	409	60
Metoprolol Tartrate	Metoprolol Tartrate	409	48
Metoprolol Succinate	Metoprolol Succinate	368	52
Pioglitazone Hcl	Pioglitazone Hcl	352	48
Clonazepam	Clonazepam	341	59
Meloxicam	Meloxicam	337	66
Montelukast Sodium	Montelukast Sodium	298	56
Levothyroxine Sodium	Levothyroxine Sodium	297	35
Alprazolam	Alprazolam	284	36
Tamsulosin Hcl	Tamsulosin Hcl	273	36
Tramadol Hcl	Tramadol Hcl	272	60
Furosemide	Furosemide	262	41
Carvedilol	Carvedilol	252	46
Allopurinol	Allopurinol	248	29
Hydrochlorothiazide	Hydrochlorothiazide	247	36
Glimepiride	Glimepiride	245	33
Memantine Hcl	Memantine Hcl	227	34
Irbesartan	Irbesartan	215	26
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	208	67
Clopidogrel	Clopidogrel Bisulfate	193	34
Tolterodine Tartrate Er	Tolterodine Tartrate	193	28
Sertraline Hcl	Sertraline Hcl	192	33
Glipizide	Glipizide	187	29
Cilostazol	Cilostazol	186	31
Temazepam	Temazepam	183	33
Latanoprost	Latanoprost	178	29
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	171	23
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	166	21
Candesartan Cilexetil	Candesartan Cilexetil	160	20
Donepezil Hcl	Donepezil Hcl	160	28
Baclofen	Baclofen	147	29
Isosorbide Mononitrate Er	Isosorbide Mononitrate	142	19
Metolazone	Metolazone	137	28
Trazodone Hcl	Trazodone Hcl	130	29
Enalapril Maleate	Enalapril Maleate	129	20
Meclizine Hcl	Meclizine Hcl	129	35
Fenofibrate	Fenofibrate	128	19
Tradjenta	Linagliptin	124	19
Lantus	Insulin Glargine,hum.Rec.Anlog	122	24
Nifedipine Er	Nifedipine	119	20
Sulindac	Sulindac	117	23
Azithromycin	Azithromycin	111	84
Finasteride	Finasteride	111	14
Rosuvastatin Calcium	Rosuvastatin Calcium	108	19
Calcitriol	Calcitriol	105	15
Quetiapine Fumarate	Quetiapine Fumarate	105	20
Glycopyrrolate	Glycopyrrolate	104	27
Doxazosin Mesylate	Doxazosin Mesylate	101	14
Nabumetone	Nabumetone	101	25
Pravastatin Sodium	Pravastatin Sodium	91	suppressed
Dexamethasone	Dexamethasone	90	66
Eliquis	Apixaban	89	17
Betamethasone Dipropionate	Betamethasone Dipropionate	86	23
Atenolol	Atenolol	78	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	76	12
Silver Sulfadiazine	Silver Sulfadiazine	72	34
Albuterol Sulfate Hfa	Albuterol Sulfate	68	21
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	65	suppressed
Permethrin	Permethrin	64	30
Citalopram Hbr	Citalopram Hydrobromide	63	14
Hydralazine Hcl	Hydralazine Hcl	62	12
Lorazepam	Lorazepam	61	13
Zolpidem Tartrate	Zolpidem Tartrate	61	suppressed
Methotrexate	Methotrexate Sodium	60	suppressed
Mometasone Furoate	Mometasone Furoate	60	28
Mirtazapine	Mirtazapine	59	13
Escitalopram Oxalate	Escitalopram Oxalate	58	11
Farxiga	Dapagliflozin Propanediol	57	12
Gemfibrozil	Gemfibrozil	57	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	57	30
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	56	17
Diclofenac Sodium	Diclofenac Sodium	54	25
Buspirone Hcl	Buspirone Hcl	51	suppressed
Diclofenac Sodium Er	Diclofenac Sodium	50	14
Levetiracetam	Levetiracetam	50	suppressed
Levofloxacin	Levofloxacin	49	39
Lansoprazole	Lansoprazole	48	suppressed
Ibuprofen	Ibuprofen	47	16
Oxybutynin Chloride	Oxybutynin Chloride	47	suppressed
Pentoxifylline	Pentoxifylline	46	suppressed
Candesartan-Hydrochlorothiazid	Candesartan/Hydrochlorothiazid	45	suppressed
Humalog	Insulin Lispro	43	suppressed
Ezetimibe	Ezetimibe	42	suppressed
Methylprednisolone	Methylprednisolone	42	31
Ciprofloxacin Hcl	Ciprofloxacin Hcl	41	28
Clonidine Hcl	Clonidine Hcl	41	suppressed
Duloxetine Hcl	Duloxetine Hcl	41	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	41	suppressed
Estradiol	Estradiol	40	suppressed
Prednisone	Prednisone	40	suppressed
Spironolactone	Spironolactone	40	suppressed
Chlorthalidone	Chlorthalidone	39	suppressed
Raloxifene Hcl	Raloxifene Hcl	38	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	37	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	36	suppressed
Naproxen	Naproxen	36	suppressed
Colchicine	Colchicine	35	suppressed
Fluticasone Propionate	Fluticasone Propionate	35	suppressed
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	35	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	35	suppressed
Ketoconazole	Ketoconazole	35	12
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	35	suppressed
Naproxen Sodium	Naproxen Sodium	35	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	34	suppressed
Betamethasone Valerate	Betamethasone Valerate	33	12
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	33	suppressed
Sure Comfort Pen Needle	Pen Needle, Diabetic	33	suppressed
Sildenafil Citrate	Sildenafil Citrate	32	suppressed
Terazosin Hcl	Terazosin Hcl	32	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	31	suppressed
Neomycin-Polymyxin-Dexameth	Neomycin/Polymyxin B/Dexametha	31	24
Sure Comfort	Syringe-Needle,insulin,0.5 Ml	31	suppressed
Amiodarone Hcl	Amiodarone Hcl	30	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	29	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	28	suppressed
Indapamide	Indapamide	28	suppressed
Warfarin Sodium	Warfarin Sodium	27	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	26	suppressed
Humulin N	Insulin Nph Human Isophane	26	suppressed
Januvia	Sitagliptin Phosphate	26	suppressed
Olanzapine	Olanzapine	26	suppressed
Theophylline Er	Theophylline Anhydrous	25	suppressed
Timolol Maleate	Timolol Maleate	25	suppressed
Verapamil Er	Verapamil Hcl	25	suppressed
Divalproex Sodium	Divalproex Sodium	24	suppressed
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	24	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	24	suppressed
Prednisolone Acetate	Prednisolone Acetate	24	suppressed
Sucralfate	Sucralfate	24	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	23	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	23	suppressed
Spiriva Respimat	Tiotropium Bromide	23	suppressed
Humalog Kwikpen U-100	Insulin Lispro	22	suppressed
Bethanechol Chloride	Bethanechol Chloride	21	suppressed
Pregabalin	Pregabalin	21	suppressed
Sure Comfort	Syringe And Needle,insulin,1ml	21	suppressed
Jardiance	Empagliflozin	20	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Nitroglycerin	Nitroglycerin	20	suppressed
Anastrozole	Anastrozole	18	suppressed
Brilinta	Ticagrelor	18	suppressed
Flecainide Acetate	Flecainide Acetate	18	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	17	suppressed
Easy Touch Pen Needle	Pen Needle, Diabetic	17	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	17	suppressed
Galantamine Hbr	Galantamine Hbr	17	suppressed
Jentadueto	Linagliptin/Metformin Hcl	17	suppressed
Valsartan	Valsartan	17	suppressed
Dorzolamide Hcl	Dorzolamide Hcl	16	suppressed
Tizanidine Hcl	Tizanidine Hcl	16	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	15	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	15	suppressed
Fluconazole	Fluconazole	15	suppressed
Insulin Lispro	Insulin Lispro	15	suppressed
Propranolol Hcl	Propranolol Hcl	15	suppressed
Sure Comfort	Syring-Needl,disp,insul,0.3 Ml	15	suppressed
Telmisartan-Hydrochlorothiazid	Telmisartan/Hydrochlorothiazid	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	14	11
Doxepin Hcl	Doxepin Hcl	14	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	14	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	14	suppressed
Amantadine	Amantadine Hcl	13	suppressed
Ampicillin Trihydrate	Ampicillin Trihydrate	13	suppressed
Flurbiprofen	Flurbiprofen	13	suppressed
Lamotrigine	Lamotrigine	13	suppressed
Mupirocin	Mupirocin	13	suppressed
Ssd	Silver Sulfadiazine	13	suppressed
Acyclovir	Acyclovir	12	suppressed
Alogliptin-Metformin	Alogliptin Benz/Metformin Hcl	12	suppressed
Invokamet	Canagliflozin/Metformin Hcl	12	suppressed
Ondansetron Hcl	Ondansetron Hcl	12	suppressed
Promethazine Hcl	Promethazine Hcl	12	suppressed
Spiriva Handihaler	Tiotropium Bromide	12	suppressed
Synjardy	Empagliflozin/Metformin Hcl	12	suppressed
Topiramate	Topiramate	12	suppressed
Torsemide	Torsemide	12	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	11	suppressed
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	11	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	11	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	11	suppressed
Estradiol-Norethindrone Acetat	Estradiol/Norethindrone Acet	11	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	11	suppressed
Jentadueto Xr	Linagliptin/Metformin Hcl	11	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	11	suppressed
Phenobarbital	Phenobarbital	11	suppressed
Tolterodine Tartrate	Tolterodine Tartrate	11	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$117.54 · 4 records	GlaxoSmithKline, LLC.	ESPRIT, REXULTI	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error